Next Article in Journal
Green Nanotechnology: Advancement in Phytoformulation Research
Previous Article in Journal
Antiproliferative Activity of (-)-Rabdosiin Isolated from Ocimum sanctum L.
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessReview

Synthetic Lethality in Lung Cancer—From the Perspective of Cancer Genomics

Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
Department of Respirology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku Chiba-shi, Chiba 260-8670, Japan
Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan
Author to whom correspondence should be addressed.
Medicines 2019, 6(1), 38;
Received: 29 January 2019 / Revised: 5 March 2019 / Accepted: 8 March 2019 / Published: 12 March 2019
(This article belongs to the Special Issue Novel Therapeutic and Preventive Approaches for Cancer)
PDF [815 KB, uploaded 12 March 2019]
  |     |  


Cancer is a genetic disease, and this concept is now widely exploited by both scientists and clinicians to develop new genotype-selective anticancer therapeutics. Although the quest of cancer genomics is in its dawn, recognition of the widespread applicability of genetic interactions with biological processes of tumorigenesis is propelling research throughout academic fields. Lung cancer is the most common cause of cancer death worldwide, with an estimated 1.6 million deaths each year. Despite the development of targeted therapies that inhibit oncogenic mutations of lung cancer cases, continued research into new therapeutic approaches is required for untreatable lung cancer patients, and the development of therapeutic modalities has proven elusive. The “synthetic lethal” approach holds the promise of delivering a therapeutic regimen that preferentially targets malignant cells while sparing normal cells. We highlight the potential challenges in synthetic lethal anticancer therapeutics that target untreatable genetic alterations in lung cancer. We also discuss both challenges and opportunities regarding the application of new synthetic lethal interactions in lung cancer. View Full-Text
Keywords: lung cancer; cancer genome; synthetic lethality lung cancer; cancer genome; synthetic lethality

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Shimomura, I.; Yamamoto, Y.; Ochiya, T. Synthetic Lethality in Lung Cancer—From the Perspective of Cancer Genomics. Medicines 2019, 6, 38.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top